newsfilter
← Latest News
GlobeNewswire·

Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren's Disease

PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), a clinical-stage biotechnology company today announced that researchers at Oxford